An analysis of prognostic factors for stage ⅢA (N2) non-small cell lung cancer after complete resection
10.3760/cma.j.issn.1004-4221.2016.10.007
- VernacularTitle:ⅢA（N2）期NSCLC术后预后因素分析
- Author:
Yuejiao LIU
;
Xiaomin LI
;
Jing WU
;
Qi LI
;
Yajuan WU
;
Yaqiong REN
;
Yuejun REN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung/surgery;
Neoplasms metastasis,postoperation;
Neoplasms recurrence,postoperation;
Choice radiotherapy
- From:
Chinese Journal of Radiation Oncology
2016;25(10):1057-1061
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the factors associated with postoperative metastasis, recurrence, and survival in patients with stage ⅢA ( N2 ) non?small cell lung cancer ( NSCLC ) , and to provide an objective basis for postoperative radiotherapy in patients. Methods Clinical data were collected from 199 patients who underwent complete resection and were diagnosed with stage ⅢA ( N2 ) NSCLC after surgery in our hospital from 2009 to 2013. The Cox regression model was used for the multivariate analyses of metastasis and recurrence. The survival rates were calculated using the Kaplan?Meier method and analyzed using the log?rank test. Results In the 199 patients, 173 had complete follow?up data. The 1?and 2?year metastasis, recurrence, and survival rates were 38?7%/52?6%, 27?8%/39?1%, and 92?5%/51?4%, respectively. The multivariate analysis showed that pathological type and two positive indices among preoperative CEA/CY211/SCC were two risk factors for metastasis ( P=0?013,0?014) . Positive lymph node number, metastatic lymph node number, lymph node metastasis rate, and two positive indices among preoperative CEA/CY211/SCC were risk factors for recurrence ( P=0?046,0?004,0?028,0?001) . All the above indices were risk factors for low survival rates ( P= 0?013 , 0?011 , 0?002,0?026 ) . Conclusions Patients with stage ⅢA ( N2 ) NSCLC who have positive lymph nodes, lymph node metastases, and two positive indices among preoperative CEA/CY211/SCC may benefit from postoperative radiotherapy.
